Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infections
Further strengthens Gedea Biotech’s broad patent portfolio pHyph has demonstrated a superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Additionally, unlike antibiotics, pHyph will not promote antimicrobial resistance Lund, Sweden, September…
Making a difference to women worldwide
Gedea Biotech has developed the world’s first antibiotic-free treatment to both treat and prevent bacterial vaginosis. The treatment is called pHyph, and is a vaginal tablet that has shown a medical effectiveness in treating bacterial vaginosis in line with antibiotics on the market, but with a…
Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launch
Lund, Sweden, May 24, 2023: Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for: An ongoing proof-of-concept study for the treatment of…
Gedea Biotech initiates EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
Up to 75% of all women are affected by vaginal infection in their lifes Self-diagnoses leads often to unnecessary and inappropriate treatment use This study aims to confirm the safety and efficacy of pHyph in VVC Lund, Sweden, May 2, 2023. Gedea Biotech today announces that the treatment of the…
Gedea Biotech obtains US-patent covering pHyph for antibiotic-free treatment and prevention of bacterial vaginosis
Important expansion of patent estate in the largest market for vaginal bacterial infections pHyph has shown superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Lund, Sweden, April 18, 2023. Swedish women’s health company Gedea Biotech announced…
Gedea Biotech appoints Anna-Karin Areskog as QA Director and receives ISO13485 certification
Lund, Sweden April 12, 2023: Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the approved certification are important milestones for achieving CE marking for pHyph, the…
Gedea Biotech awarded SEK 3M from SWElife and MedTech4Health for groundbreaking antibiotic free women’s health trial
Impact on microbiome could be key to preventing vulvovaginal infection recurrence Lund, Sweden, April 4, 2023: Gedea Biotech today announced it has been awarded SEK 3M grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge…
Two mentions and one article in three publications during end of November
News The results from the NEFERTITI-study have received much attention since they were first published in a press release from October 11th. During the last week of November, there were no less than three publications that mentioned Gedea and were spread through e.g., Twitter and LinkedIn. First…
Gedea Biotech reports results from placebo-controlled clinical trial of pHyph, an antibiotic-free treatment for bacterial vaginosis
Uppdated 2022-11-14 - Symptom reduction was seen in 90% of patients and absence of symptoms was noted in 70% of patients - Clinical cure rate was 50,4% in the pHyph group, which is in line with many antibiotic treatments on the market - The rate of recurrence of BV was substantially lower at day 35…
Gedea Biotech to Start EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
PRESS RELEASE Gedea Biotech today announces that it has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will start the EpHect clinical study of its lead product, pHyph, a vaginal tablet for topical treatment. The open-labelled study is designed to…